Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis

Journal of Clinical Investigation

Volumn 126, Issue 6, 2016, Pages 2280-2294

  Gebremariam, Teclegiorgis ^a   Lin, Lin ^a   Liu, Mingfu ^a   Kontoyiannis, Dimitrios P ^b   French, Samuel ^a,c   Edwards, John E ^a,c   Filler, Scott G ^a,c   Ibrahim, Ashraf S ^a,c  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; BICARBONATE; FUNGAL PROTEIN; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; IRON; PHENANTHROLINE; PROTEIN COTH; TRANSFERRIN; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; COTH2 GENE; COTH3 GENE; DIABETIC KETOACIDOSIS; ENDOTHELIUM CELL; EX VIVO STUDY; FUNGAL GENE; FUNGUS GROWTH; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; LACTIC ACIDOSIS; MALE; MOUSE; MUCORMYCOSIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHIZOPUS ORYZAE; UPREGULATION; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; RHIZOPUS; VIRULENCE;

3-HYDROXYBUTYRIC ACID; ANIMALS; DIABETIC KETOACIDOSIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FUNGAL PROTEINS; GLUCOSE; HEAT-SHOCK PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; IRON; MALE; MICE; MICE, INBRED ICR; MUCORMYCOSIS; RHIZOPUS; SODIUM BICARBONATE; VIRULENCE;

EID: 84974601930     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82744     Document Type: Article

References (38)

1. Sugar AM. Agents of mucomycosis and related species. In:Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol. 2. 6th ed. Philadelphia, PA, USA: Elsevier Churchill Livingstone; 2005:2973-2984.
2. Ibrahim AS, Edwards JE Jr, Filler SG, Spellberg B. Mucormycosis and Entomophthoramycosis (Zygomycosis). In:Kauffman CA, Pappas PP, Sobel JD, Dismukes WE, eds. Essentials of Clinical Mycology. 2nd ed. New York, New York, USA: Springer; 2011:265-280.
3. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73(2):778-783.
4. Gebremariam T, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest. 2014;124(1):237-250.
5. Liu M, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914-1924.
6. UpToDate. www.uptodate.com. Accessed April 6, 2016.
7. Fulop M, Hoberman HD, Rascoff JH, Bonheim NA, Dreyer NP, Tannenbaum H. Lactic acidosis in diabetic patients. Arch Intern Med. 1976;136(9):987-990.
8. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31(12):1109-1114.
9. Grinberg N, Elazar S, Rosenshine I, Shpigel NY. Beta-hydroxybutyrate abrogates formation of bovine neutrophil extracellular traps and bactericidal activity against mammary pathogenic Escherichia coli. Infect Immun. 2008;76(6):2802-2807.
10. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr. Ibrahim AS. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2004;48(5):1908-1911.
11. Im MS, Ahn HS, Cho HJ, Kim KB, Lee HY. Diabetic ketoacidosis associated with acute pancreatitis in a heart transplant recipient treated with tacrolimus. Exp Clin Transplant. 2013;11(1):72-74.
12. Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D. A prospective, multicenter, randomized, controlled study: the correction of metabolic acidosis with use of bicarbonate in Chronic Renal Insufficiency (UBI) Study. J Nephrol. 2012;25(3):437-440.
13. Ibrahim AS, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010;77(3):587-604.
14. Oswal NP, Gadre PK, Sathe P, Gadre KS. Mucormycosis of mandible with unfavorable outcome. Case Rep Dent. 2012;2012:257940.
15. Imbernon A, et al. Successful therapy of progressive rhino-orbital mucormycosis caused by Rhizopus arrhizus with combined and sequential antifungal therapy, surgery and hyperbaric therapy. Med Mycol Case Rep. 2014;6:51-54.
16. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001; 69(4):522-530.
17. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21(6):620-625.
18. Marsili G, Tacconi R, Cipriani S. Determination of serum iron and the total iron-binding capacity with a new chromogen, 4-aminophenazone. Ric Clin Lab. 1980;10(2):423-429.
19. Cantinieaux B, et al. Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis. J Lab Clin Med. 1999;133(4):353-361.
20. Guo D, et al. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol. 2002;58(2):134-142.
21. Omara FO, Blakley BR, Huang HS. Effect of iron status on endotoxin-induced mortality, phagocytosis and interleukin-1 alpha and tumor necrosis factor-alpha production. Vet Hum Toxicol. 1994;36(5):423-428.
22. Omara FO, Blakley BR. The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br J Nutr. 1994;72(6):899-909.
23. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191(7):1180-1187.
24. Savage MW, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011;28(5):508-515.
25. Skitch SA, Valani R. Treatment of pediatric diabetic ketoacidosis in Canada: a review of treatment protocols from Canadian pediatric emergency departments. CJEM. 2015;17(6):656-661.
26. Westerberg DP. Diabetic ketoacidosis: evaluation and treatment. Am Fam Physician. 2013;87(5):337-346.
27. Roden MM, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653.
28. Abraham P, Govil S, Srivastava VM, Ganesh A. Spontaneous regression of pulmonary mucormycosis. Postgrad Med J. 1995;71(840):632-634.
29. Spellberg B, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715-722.
30. Spellberg B, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122-3125.
31. Ma LJ, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet. 2009;5(7):e1000549.
32. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52(11):2745-2756.
33. Ibrahim AS, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117(9):2649-2657.
34. Ibrahim AS, et al. Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis. J Infect Dis. 2008;198(7):1083-1090.
35. Tsuchimori N, Sharkey LL, Fonzi WA, French SW, Edwards JE Jr, Filler SG. Reduced virulence of HWP1-deficient mutants of Candida albicans and their interactions with host cells. Infect Immun. 2000;68(4):1997-2002.
36. Eiger SM, Kirsch JR, D'Alecy LG. Hypoxic tolerance enhanced by β-hydroxybutyrate-glucagon in the mouse. Stroke. 1980;11(5):513-517.
37. Robey IF, Martin NK. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer. 2011;11:235.
38. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7):2670-2677.